Small cell lung cancer
39
Small cell lung cancer Haobin Chen, M.D., Ph.D. Assistant Clinical Investigator TGIB, NCI
Transcript of Small cell lung cancer
Small cell lung cancerHaobin Chen, M.D., Ph.D.
Assistant Clinical Investigator
TGIB, NCI
SCLC morphology
Small cell lung cancer (SCLC)
Difference between SCLC and NSCLC
SCLC is considered as a recalcitrant cancer
• Recalcitrant Cancer Research Act of 2012.
• Recalcitrant cancer: • Have a 5-year relative survival rate of less than 20% • Estimated to cause the death of at least 30,000 individuals in the United
States per year.
• NCI identified four major obstacles to progress in 2014: • Continuing risk of developing the disease that remains for decades after
smoking cessation. • Most patients have widely metastatic tumors at the time of diagnosis. • Rapid development of resistance to chemotherapy in more than 95% of
SCLC patients. • Lack of tumor tissue for clinical, molecular , and cell biological studies.
SCLC is difficult to treat
SCLC therapies
How is SCLC formed?
What causes SCLC?
Mutational burden
Genomic abnormalities
Genomic changes
TP53 and RB1
Mutations in SCLC
Loss of TP53 and RB1 genes
SCLC mouse models
Mouse models
Cell origin
SCLC origin
SCLC tumorigenesis
SCLC heterogeneity
Classic and variant SCLC
SCLC molecular subtypes
Subtype classification
Intratumoral heterogeneity
SCLC plasticity
Platinum-resistance
Implications
New therapies
Drug screens
SCLC susceptibility
Subtype therapy
SCLC subtype treatment
Synthetic lethality
Replication stress
